Navigation Links
Cell Biosciences to Acquire Convergent Bioscience
Date:10/13/2010

SANTA CLARA, Calif., Oct. 13 /PRNewswire/ -- Cell Biosciences, Inc. today announced that it has entered into a definitive agreement to acquire Convergent Bioscience Ltd. for approximately U.S. $12 million in cash. The transaction is expected to close by the end of October, 2010.

Convergent Bioscience was founded in 1995 and employs 45 people, primarily at its headquarters in Toronto, Ontario. Convergent pioneered the use of imaging capillary electrophoresis for protein charge heterogeneity characterization, a critical quality control measurement performed during protein biologics production. Convergent's products have become the acknowledged gold standard for biologics charge heterogeneity quality control monitoring. More than 320 systems have been purchased by over 100 Pharma and Biotech companies globally for this purpose. Convergent's 2010 revenues are expected to be near U.S. $8 million.

This strategic acquisition will significantly expand Cell Biosciences' portfolio of protein analysis products and transform Cell Biosciences into the premier provider of capillary-based protein analysis technology. By acquiring Convergent Bioscience, with its strong position in biologics quality control, Cell Biosciences will gain access to an attractive, high-growth segment of the protein therapeutics market. This acquisition marks an important step toward Cell Biosciences' strategic goal of becoming a leading global provider of protein analysis technologies.

Commenting on the transaction, Tim Harkness, President and Chief Executive Officer of Cell Biosciences, said, "The strategic fit between Cell Biosciences and Convergent Bioscience is nearly perfect. Our NanoPro systems and the Convergent iCE280 are based upon similar technologies, but each platform has been optimized for distinct applications in distinct markets. We expect to realize immediate synergies across both organizations, ultimately leading to groundbreaking next-generation products for our
'/>"/>

SOURCE Cell Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
2. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
3. YM BioSciences reports fiscal year end 2010 operational and financial results
4. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
7. Signum Biosciences Names Braham Shroot as Chief Executive Officer
8. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
9. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
10. Ambit Biosciences Announces Transition in Company Leadership
11. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... WI (PRWEB) , ... September 01, 2015 , ... In ... Venice expertly transports the reader to a not-so-distant future faced with an Ebola pandemic ... beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, and who ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new Clinical ... joint problems can be caused by injuries and abnormalities of the cervical spine. ... or of the spinal cord itself. This can manifest itself as any or ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, ... and pain management space join prominent academics and key investors for Neuro Advance ... Medical School in Boston. , Neuro Advance Boston focuses on the latest ...
(Date:9/1/2015)... N.C. , Sept. 1, 2015   ... to facilitating the relationship between doctors and patients, ... Durham, N.C. -based venture capital ... strength and business association with Bull City Venture ... Malik , Medfusion Founder and Executive Chairman. "Both ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... PALO ALTO, Calif., Sept. 26 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... New York, NY on October 8,2007 at 8:00 ... the presentation may be accessed by visiting the,Investors ...
... announced,today that Mr. Jeffrey H. Buchalter has been ... With more than 20 years of experience in,product ... Mr. Buchalter is well poised to work with ... toward,commercializing its pipeline. "We are honored that ...
... Deal Includes up to $100MM in License Fees ... 26 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), ... with Japan Tobacco Inc. (JT) (TSE: 2914) and ... business subsidiary,under which JT and Torii will hold ...
Cached Biology Technology:Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 2Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 3Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 4
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... "intriguing" discovery that a natural plant hormone, applied to ... The study is scheduled for the Sept. 23 issue ... , a bi-weekly publication. Jing Quan Yu and ... production for the world,s growing population. Farmers worldwide use ...
... of Standards and Technology (NIST) has demonstrated a ... elusive hazards such as concealed explosives and toxins, ... soil by wind and rain. The prototype method ... traces of these materials, which are polarlike water ...
... to be able to find explosive materials and persons ... such searches, the National Institute of Standards and Technology ... has developed a new certified reference material, Standard Reference ... and laboratory assay methods, the SRM will be helpful ...
Cached Biology News:Prototype NIST method detects and measures elusive hazards 2New NIST trace explosives standard slated for homeland security duty 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Biology Products: